Title: The Chk1 inhibitor SRA737 demonstrates chemical synthetic lethality with replication stress-inducing agents including novel low-dose gemcitabine in preclinical models of cancer.
Title: The Chk1 inhibitor, SRA737, demonstrates chemical synthetic lethality with replication stress-inducing agents, including novel low-dose gemcitabine, in preclinical models of cancer.